Your session is about to expire
← Back to Search
Cancer Vaccine
Treatment for Glioblastoma (DCVax-L EAP Trial)
N/A
Waitlist Available
Research Sponsored by Northwest Biotherapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
The study is an open-label expanded access study for patients for whom vaccine was manufactured during the Northwest Biotherapeutics' 020221 DCVax-L for GBM screening process, but who subsequently failed to meet specific enrollment criteria. Patients will receive therapy per investigator discretion (standard of care) as well as active vaccine per the 020221 protocol administration schedule. It is estimated that approximately 99 patients will enroll in this study.
Eligible Conditions
- Glioblastoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Northwest BiotherapeuticsLead Sponsor
7 Previous Clinical Trials
468 Total Patients Enrolled
2 Trials studying Glioblastoma
348 Patients Enrolled for Glioblastoma
Share this study with friends
Copy Link
Messenger